813 Results
Sort By:
Published on September 27, 2017
Proposed 2018 Medicare payment rates for clinical diagnostic laboratory tests, calculated under the Protecting Access to Medicare Act (PAMA), have drawn anger from labs that process the tests and others. The Centers for Medicare & Medicaid Services (CMS) said the proposed rates would save about $670 million in Part B…
Published on September 22, 2017
Patient-centric genomics company DxTerity announced it will collaborate with California-based City or Hope Medical Center on the clinical development of a blood test intended to predict whether patients about to undergo radiation therapy for cancer are likely to benefit from the treatment. The test will also seek to provide information…
Published on September 15, 2017
PerkinElmer said it will provide support services to the Whole Genome Sequencing (WGS) Diagnostic Program of In-Depth Genomics (IDG) through a collaboration designed to bring genetic diagnosis to neurology patients across a range of conditions that include rare and orphan disorders. Through the collaboration—whose value was not disclosed—PerkinElmer Genetics, the…
Published on September 12, 2017
Researchers have constructed the first-ever predictive model of inflammatory bowel disease (IBD), revealing the complexity of its immune network through a multi-omics approach—a complexity that they hope will yield potential targets for new treatments. The model consists of individual networks constructed using molecular data generated from intestinal tissue samples isolated…
Published on September 5, 2017
A study published today by researchers at Memorial Sloan Kettering Cancer Center (MSK) has concluded that simultaneous sequencing of tumor DNA and normal tissue for a broad panel of cancer-related genes may detect more potentially clinically significant heritable mutations than a targeted approach based on current clinical guidelines. The study…
Published on August 21, 2017
OmniSeq said today its Immune Report Card SM and OmniSeq ComprehensiveSM clinical assays will be distributed by LabCorp under an exclusive agreement whose value was not disclosed. LabCorp will also participate in the upcoming series B financing of OmniSeq, a subsidiary of the Roswell Park Cancer Institute in Buffalo, NY,…
Published on August 16, 2017
Researchers at the Indiana University (IU) School of Medicine claim they have developed blood tests for detecting suicide risk both in the general population and for specific types groups at risk for suicide. In addition, the team showed how two apps—one based on a suicide-risk checklist, and the other on…
Published on August 3, 2017
A week after the first participants began enrolling in the million-person “All of Us” research cohort piece of the NIH’s Precision Medicine Initiative, Quest Diagnostics laid groundwork for launching its own personalized treatment effort in Texas, focused on cancer. The company has put the first pieces of this vision in…
Published on August 1, 2017
It has been roughly nine years since next-generation sequencing (NGS) methods made their appearance in research labs. Largely led—at least initially—by sequencing heavyweight Illumina, the new technologies allowed researchers and molecular biologists in clinical labs to move from sequencing single genes to today where it is routinely used to analyze…
Published on July 30, 2017
Heidi Rehm, Ph.D., is a leader in translational medicine, having spearheaded the creation of the Laboratory for Molecular Medicine at Harvard-Partners Center for Genetics and Genomics in 2002 (now Partners Healthcare Personalized Medicine) and via her work at the Broad Institute involving both rare disease gene discovery, medical and population…
Published on July 18, 2017
Agena Bioscience said today it will co-promote its MassARRAY® DX clinical diagnostics technology with HeartGenetics' CE-IVD marked products for cardiovascular testing, through a co-marketing alliance whose value was not disclosed. Agena’s MassARRAY DX, which is also CE-IVD marked, is a non-fluorescent detection platform utilizing mass spectrometry to accurately measure PCR-derived…
Published on June 28, 2017
Genoptix plans to develop clinical diagnostics for selected hematologic oncology indications in the U.S. using Bionano Genomics’ Saphyr System, the companies said today, through a strategic alliance whose value was not disclosed. Development efforts will focus on indications where detection of large structural variations of the genome is required for…
Published on June 28, 2017
New research published in Proceedings of the National Academy of Sciences shows that DNA methylation can provide effective markers for predicting the prognosis and survival of four cancers. “We report that methylation patterns can predict the prognosis and survival, with good correlation between differential methylation of CpG sites and expression…
Published on June 23, 2017
In what Thermo Fisher Scientific officials are calling an “historic, path-breaking event,” the FDA has granted premarket approval to the company’s Oncomine Dx Target Test, which screens tumor samples for biomarkers associated with three FDA-approved drugs for non-small cell lung cancer (NSCLC). The panel-based test evaluates 23 different biomarkers simultaneously and…
Published on June 20, 2017
Agena Bioscience said today that its MassARRAY® System has been chosen by Assurex Health for laboratory setup and sample processing of its GeneSight Psychotropic test, under an expanded partnership whose value was not disclosed. GeneSight Psychotropic is a laboratory-developed test designed to help clinicians analyze how a patient's genetic make-up…